Valuation: Corbus Pharmaceuticals Holdings, Inc.

Market Cap 167M 146M 135M 124M 234M 16.08B 239M 1.61B 633M 7.87B 627M 613M 27.1B P/E 2026 *
-1.93x
P/E 2027 * -1.7x
Enterprise Value 167M 146M 135M 124M 234M 16.08B 239M 1.61B 633M 7.87B 627M 613M 27.1B EV / Sales 2026 *
150x
EV / Sales 2027 * 69.6x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Corbus Pharmaceuticals Holdings, Inc.

1 day-2.98%
1 week-9.89%
Current month-3.36%
1 month+13.02%
3 months-11.89%
6 months+8.67%
Current year+10.30%
1 week 7.34
Extreme 7.335
8.16
1 month 6.9
Extreme 6.9
8.16
Current year 5.8
Extreme 5.8
11.26
1 year 5.8
Extreme 5.8
18.4
3 years 3.86
Extreme 3.86
56
5 years 2.99
Extreme 2.988
56
10 years 2.99
Extreme 2.988
330
Manager TitleAgeSince
Chief Executive Officer 51 2014-04-10
Director of Finance/CFO 68 2014-04-10
Chief Tech/Sci/R&D Officer 48 2026-07-05
Director TitleAgeSince
Director/Board Member 51 2014-04-10
Director/Board Member 68 2018-06-04
Chairman 54 2025-05-14
Change 5-day change 1-year change 3-year change Capi.($)
-2.98%-9.89% - - 167M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.79%-2.62%+40.77%+183.80% 25.95B
Weighted average by Cap. -2.80%-2.36%+40.12%+144.11%

Financials

2026 *2027 *
Net sales 1.11M 971K 896K 826K 1.56M 107M 1.59M 10.71M 4.21M 52.41M 4.17M 4.08M 180M 2.4M 2.1M 1.94M 1.78M 3.36M 231M 3.44M 23.13M 9.1M 113M 9.01M 8.82M 390M
Net income -97.64M -85.32M -78.74M -72.57M -137M -9.4B -140M -941M -370M -4.61B -367M -359M -15.85B -123M -107M -98.97M -91.23M -172M -11.82B -176M -1.18B -465M -5.79B -461M -451M -19.93B
Net Debt - -
Logo Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Employees
36
Date Price Change
26-07-17 €7.335 -2.98%
26-07-16 €7.560 -0.59%
26-07-15 €7.605 -0.26%
26-07-14 €7.625 -6.50%
26-07-13 €8.155 +0.18%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.010USD
Average target price
35.30USD
Spread / Average Target
+291.79%

Quarterly revenue - Rate of surprise